Copy Trading Strategies: Exposure, Overlap and Evaluation
Compare ways to allocate across copied providers and define a fair evaluation without assuming that more providers create diversification.
Choose the portfolio objective
A copied portfolio can be designed around an exposure budget, a particular strategy family or an operational constraint. Those are different objectives. Define the maximum exposure you intend to permit, the instruments allowed and the evidence needed for a provider to remain eligible. A return target alone does not describe the risk that can be taken to pursue it.
Look through provider labels
Three providers can all hold the same leveraged currency position. Equal capital allocation then spreads operational relationships without necessarily spreading market risk. Inspect instruments, direction, concentration and behavior during adverse periods. Correlations estimated from a short record are unstable and can miss shared tail risk.
A budget illustration
Suppose a fictional 10,000 account assigns 2,000 to each of three providers and leaves 4,000 unallocated. That does not mean only 6,000 can be lost: leverage, margin arrangements and platform rules determine exposure and possible loss. A capital allocation label must be reconciled to actual positions and contractual protections.
Compare policies on the same evidence
| Policy | Question to test |
|---|---|
| Equal capital allocation | Does it produce unequal risk because providers use different leverage? |
| Risk-budget allocation | Are risk estimates stable and based on sufficient records? |
| Provider eligibility rules | Were rules chosen before evaluating the next period? |
| Periodic review | What changes justify an action rather than hindsight performance chasing? |
Retain the rejected candidates
A study that considers only today’s surviving providers can omit discontinued or failed records. Freeze the candidate universe, selection date, fees and allocation rule. Evaluate subsequent outcomes with the same cash-flow treatment. This guide presents a research protocol, not an original backtest or a winning provider list.
Related guides and tools
Sources and scope
Primary documentation checked 2026-10-16. This original guide does not reproduce the former page or claim an original product trial, audited return or professional financial review.